Reteplase, Recombinant and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Reteplase, Recombinant
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Apixaban (Eliquis) is a blood thinner that helps stop dangerous clots from forming. Reteplase is a powerful clot-buster given in the hospital to break up a clot that has already formed, such as during a heart attack. Both of these work on your body's clotting system, so using them together can add up and raise your risk of serious bleeding.
The good news is that when both are truly needed, your hospital care team watches you very closely for any signs of bleeding and checks your blood work. Please tell your care team about every medicine you take, and let them know right away if you notice unusual bruising, bleeding, or feel dizzy or weak.
Effect: Additive hemostatic impairment increasing the risk of major bleeding when apixaban (direct oral factor Xa inhibitor) is combined with reteplase (recombinant fibrinolytic).
Mechanism: Pharmacodynamic additive effect; apixaban reduces thrombin generation while reteplase promotes fibrinolysis. Neither is a prodrug; this is a PD, not PK, interaction.
- Severity: Major. Onset: unspecified. Evidence: theoretical.
- Management: Monitor clinically for external/internal bleeding, observe surgical wound drainage, and perform close laboratory monitoring (appropriate coagulation tests, PT, serial Hb). Suspect bleeding if Hb falls or BP drops.
What happens
An increased risk of bleeding
Interaction Deep Dive
When an anticoagulant is taken together with a fibrinolytic agent (for example, a thrombolytic), additive effects may raise the likelihood of major bleeding events1. Safe joint administration has been shown in two studies, one involving low-dose warfarin 4 and the other low-intensity warfarin therapy, meaning an INR of 1.7 or below, alongside a thrombolytic agent 5. Nevertheless, when combining an anticoagulant with a fibrinolytic agent cannot be avoided, patients require clinical monitoring for indications of either external or internal bleeding. Laboratory monitoring is likewise recommended 2. Surgical wound drainage should be watched closely. Bleeding should be suspected if Hb levels drop or if blood pressure declines 3.
Why it happens (mechanism)
Additive effects
How to manage this interaction
These two are usually only combined in an emergency hospital setting, where your team manages the added bleeding risk directly. Typically they will:
- Watch closely for outside bleeding and signs of internal bleeding.
- Run blood tests, including clotting tests and prothrombin time, and check hemoglobin levels over time.
- Keep an eye on any surgical wound drainage and your blood pressure.
What you can do: keep taking your medicines exactly as prescribed, and never stop or change them on your own. Tell your pharmacist or doctor about all your medications, and report any unusual bruising, bleeding, dizziness, or weakness right away so your care team can act quickly.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) In clinical studies of patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intervention (PCI), giving bivalirudin together with thrombolytic agents, glycoprotein IIb/IIIa inhibitors, warfarin, or heparin was linked to a higher risk of major bleeding events compared with patients who did not receive these concurrent medications 1. Any agent that could raise the risk of bleeding should be stopped before starting desirudin therapy 2.
b) Even though reduced doses were employed during the streptokinase infusion, warfarin administration caused no problems, according to a Finnish study that assessed streptokinase together with oral anticoagulants for treating DVT. Forty-four patients were initially given warfarin 0.5 mg and streptokinase 600,000 international units. Streptokinase 600,000 international units/hour was maintained for 3 days, and phlebography was carried out to assess resolution of the thrombotic occlusion. If lysis was incomplete, treatment continued for another 3 days. When required, warfarin was administered to maintain the protein phosphatase (PP) activity level at 0.1 to 0.2. Bleeding was the cause of treatment discontinuation in 8 of the 44 patients (18.2%). Although this study records concurrent use of oral anticoagulants and streptokinase, both the anticoagulant and streptokinase were started at the same time. Because 3 to 5 days are needed before hypoprothrombinemia develops, these patients did not undergo the true interaction of streptokinase's thrombolytic effect combined with hypoprothrombinemia caused by concomitant warfarin 4.
c) In a study examining registry data from 45,074 patients who were given IV tissue plasminogen activator for acute ischemic stroke, there was no significant rise in the risk of symptomatic intracerebral hemorrhage or death among patients on warfarin therapy with an INR of 1.7 or less (n=768) compared with patients not receiving warfarin (n=43,651) after adjusting for age, stroke severity, and comorbidities 5.
Common questions
Can I take Reteplase, Recombinant and Apixaban together?
Combining apixaban with reteplase adds up to a higher risk of serious bleeding, so this pairing is used only when necessary and under close hospital monitoring. Watch for any signs of bleeding and report them immediately. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Reteplase, Recombinant and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Reteplase, Recombinant and Apixaban interaction managed?
These two are usually only combined in an emergency hospital setting, where your team manages the added bleeding risk directly. Typically they will: Watch closely for outside bleeding and signs of internal bleeding. Run blood tests, including clotting tests and prothrombin time, and check hemoglobin levels over time. Keep an eye on any surgical wound drainage and your blood pressure. What you can… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Reteplase, Recombinant or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: ANGIOMAX(R) IV injection, bivalirudin IV injection. The Medicines Company, Parsippany, NJ, 2005.
- Product Information: Iprivask(TM), desirudin for injection. Aventis Pharmaceuticals Inc. Bridgewater, NJ, 2003.
- Product Information: Xarelto(R) oral film-coated tablets, rivaroxaban oral film-coated tablets. Bayer HealthCare (per manufacturer), Leverkusen, Germany, 2008. DailyMed
- Jarvinen P, Aromaa U, Roiha M, et al: Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klin Wochenschr 1978; 56:801-804. PubMed
- Mazya MV, Lees KR, Markus R, et al: Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013; 74(2):266-274. DOI
Keep reading about Apixaban
Keep reading about Reteplase, Recombinant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist